Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects (NCT03139305)

Usually NOT eligible if any of the following apply:

• Exclusion Criteria
• Treatment with any medication known to significantly impact body weight or energy metabolism (e.g., weight loss medications, atypical antipsychotics) within 3 months prior to screening except for stable physiological hormone replacement therapy (i.e., thyroid hormone, estrogen).
• Treatment with a selective serotonin reuptake inhibitor, a medication for depression or apomorphine within one week prior to screening due to interaction with Zofran.
• History of bariatric surgery.
• Current liver, renal, pulmonary, cardiac, oncologic, metabolic, gastrointestinal, or hematologic disease which the Investigator believes is clinically significant, including: a. Liver disease or liver injury as indicated by abnormal liver function tests (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, serum bilirubin) \>3 × upper limit of normal (ULN), or history of hepatic cirrhosis.
• Impaired renal function as indicated by an estimated glomerular filtration rate (eGFR) \<60 mL/min or urine albumin-to-creatinine ratio \>35 mg/mmol.
• Significant cardiovascular disease, including Class III or greater congestive heart failure (CHF), coronary artery disease, second degree or greater heart block, or clinically significant arrhythmias; baseline second degree or greater heart block or prolonged QT syndrome (QTc interval ≥470 msec); or any major cardiovascular event within the last 3 years (including myocardial infarction \[MI\], transient ischemic attack, cerebrovascular accident \[CVA\], angina, and hospitalization due to CHF,transient ischemic attack, and CVA).
• Metabolic, or other endocrine disorders, including diagnosis of type 1 or type 2 diabetes mellitus \[HbA1c ≥6.5%\]), inadequately treated hyperthyroidism (thyroid stimulating hormone \[TSH\] below normal range) or hypothyroidism (TSH \>ULN \<10 U/mL and symptomatic or TSH \>10 U/mL), Cushing's disease/syndrome, Addison's disease, hypogonadism, or genetic disorders linked to obesity.
• History of irritable bowel disease, recurrent nausea, or vomiting.
• Anemia (hemoglobin \<12 g/dL in males, \<11 g/dL in females).
• History of dyslipidemia: Fasting triglycerides (TG) \>500 mg/dL and low-density lipoproteins (LDL) \>250 mg/dL.
• Self-reported history of infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).